IL208895A0 - Nmda receptor antagonists for the treatment of neuropsychiatric disorders - Google Patents

Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Info

Publication number
IL208895A0
IL208895A0 IL208895A IL20889510A IL208895A0 IL 208895 A0 IL208895 A0 IL 208895A0 IL 208895 A IL208895 A IL 208895A IL 20889510 A IL20889510 A IL 20889510A IL 208895 A0 IL208895 A0 IL 208895A0
Authority
IL
Israel
Prior art keywords
treatment
receptor antagonists
nmda receptor
neuropsychiatric disorders
neuropsychiatric
Prior art date
Application number
IL208895A
Other languages
English (en)
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of IL208895A0 publication Critical patent/IL208895A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL208895A 2008-05-09 2010-10-24 Nmda receptor antagonists for the treatment of neuropsychiatric disorders IL208895A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12709808P 2008-05-09 2008-05-09
PCT/US2009/043502 WO2009137843A2 (en) 2008-05-09 2009-05-11 Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
IL208895A0 true IL208895A0 (en) 2011-01-31

Family

ID=41265475

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208895A IL208895A0 (en) 2008-05-09 2010-10-24 Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Country Status (16)

Country Link
US (1) US20110160223A1 (US07652168-20100126-C00055.png)
EP (1) EP2296658A4 (US07652168-20100126-C00055.png)
JP (1) JP2011520815A (US07652168-20100126-C00055.png)
KR (1) KR20110016891A (US07652168-20100126-C00055.png)
CN (1) CN102762207A (US07652168-20100126-C00055.png)
AU (1) AU2009244082A1 (US07652168-20100126-C00055.png)
BR (1) BRPI0912362A2 (US07652168-20100126-C00055.png)
CA (1) CA2722776A1 (US07652168-20100126-C00055.png)
CO (1) CO6341558A2 (US07652168-20100126-C00055.png)
EA (1) EA020339B1 (US07652168-20100126-C00055.png)
IL (1) IL208895A0 (US07652168-20100126-C00055.png)
MX (1) MX2010012186A (US07652168-20100126-C00055.png)
NZ (1) NZ589764A (US07652168-20100126-C00055.png)
SG (1) SG195568A1 (US07652168-20100126-C00055.png)
WO (1) WO2009137843A2 (US07652168-20100126-C00055.png)
ZA (1) ZA201007958B (US07652168-20100126-C00055.png)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN06631A (US07652168-20100126-C00055.png) 2010-02-16 2015-10-23 Pfizer
ES2951664T3 (es) 2011-09-08 2023-10-24 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
EP3932932A1 (en) 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroactive steriods and methods of use thereof
WO2014210456A1 (en) 2013-06-28 2014-12-31 Emory University Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2015330906A1 (en) * 2014-10-07 2017-04-27 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
MA42409A (fr) * 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
RU2021100620A (ru) 2015-07-06 2021-01-29 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
MY197698A (en) 2015-07-06 2023-07-06 Sage Therapeutics Inc Oxysterols and methods of use thereof
ES2843724T3 (es) 2015-11-30 2021-07-20 Inst Nat Sante Rech Med Antagonistas de NMDAR para el tratamiento de la angiogénesis tumoral
LT3436022T (lt) 2016-04-01 2022-06-27 Sage Therapeutics, Inc. Oksisteroliai ir jų panaudojimo būdai
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
CN110023323A (zh) 2016-09-30 2019-07-16 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
MA46565A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN109803656B (zh) * 2017-10-09 2021-08-31 华南农业大学 一种抗白色念珠菌的化合物及其制备方法和应用
WO2019191424A1 (en) 2018-03-28 2019-10-03 Emory University Glun2c/d subunit selective antagonists of the n-methyl-d-aspartate receptor
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
CN114539129B (zh) * 2020-11-18 2023-06-09 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途
WO2023034589A1 (en) * 2021-09-02 2023-03-09 Emory University Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2824677A1 (de) * 1978-06-06 1979-12-20 Hoechst Ag Neue substituierte phenylpiperazinderivate und verfahren zu deren herstellung
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
CN85108214A (zh) * 1984-11-22 1986-08-20 赫彻斯特股份公司 新的取代的苯基哌嗪衍生物及其药物的制造方法
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
GB9005318D0 (en) * 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
KR100599022B1 (ko) * 1997-10-31 2006-07-12 다이이치 아스비오파마 가부시키가이샤 아릴피페리디노프로판올 및 아릴피페라지노프로판올 유도체 및이를 함유하는 약제
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
WO2002028814A2 (en) * 2000-10-06 2002-04-11 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
DE10248925A1 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität
MXPA05012325A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
HUP0401526A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use
CA2578217A1 (en) * 2004-08-23 2006-03-02 Emory University Improved selection of ph-dependent compounds for in vivo therapy
CA2614833A1 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2, 3-disubstituted tropanes for the treatment of disorders of sexual desire
AR055203A1 (es) * 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
EP2170334B1 (en) * 2007-06-29 2021-03-17 Emory University Nmda receptor antagonists for neuroprotection

Also Published As

Publication number Publication date
JP2011520815A (ja) 2011-07-21
CN102762207A (zh) 2012-10-31
NZ589764A (en) 2012-10-26
KR20110016891A (ko) 2011-02-18
WO2009137843A9 (en) 2010-03-11
EP2296658A4 (en) 2014-01-15
MX2010012186A (es) 2011-02-22
WO2009137843A2 (en) 2009-11-12
AU2009244082A1 (en) 2009-11-12
BRPI0912362A2 (pt) 2015-10-06
EA201071291A2 (ru) 2011-04-29
EP2296658A2 (en) 2011-03-23
US20110160223A1 (en) 2011-06-30
SG195568A1 (en) 2013-12-30
ZA201007958B (en) 2011-07-27
CA2722776A1 (en) 2009-11-12
EA201071291A3 (ru) 2014-02-28
CO6341558A2 (es) 2011-11-21
EA020339B1 (ru) 2014-10-30

Similar Documents

Publication Publication Date Title
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
HK1244694A1 (zh) 新穎的胰高血糖素受體拮抗劑
EP2215049A4 (en) P2X3 RECEPTOR ANTAGONISTS USED IN THE TREATMENT OF PAIN
EP2358371A4 (en) ANTAGONISTS OF THE P2X3 RECEPTOR FOR THE TREATMENT OF PAIN
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
EP2215048A4 (en) P2X3 RECEPTOR ANTAGONISTS USED IN THE TREATMENT OF PAIN
EP2411001A4 (en) P2X3 RECEPTOR ANTAGONISTS FOR PAIN TREATMENT
EP2410857A4 (en) ANTAGONISTS OF THE P2X3 RECEPTOR FOR THE TREATMENT OF PAIN
EP2350024A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF ENDOTHELIN RECEPTOR ANTAGONISTS
ZA201006694B (en) Modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto
IL212551A0 (en) Cxcr4 receptor compounds
HK1136302A1 (en) Progesterone receptor antagonists
ZA201006587B (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
HRP20180531T1 (hr) Antagonisti serotoninskog 5-ht3 receptora za uporabu u liječenju površina vestibularnih lezija
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
IL209318A0 (en) Bicyclic compounds having activity at the cxcr4 receptor
HK1160642A1 (en) Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists via
HUE045270T2 (hu) FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
IL200380A0 (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
EP2341919A4 (en) CGRP RECEPTOR ANTAGONISTS
EP2340025A4 (en) CGRP RECEPTOR ANTAGONISTS
IL205432A0 (en) Method of identigfying safe nmda receptor antagonists
EP2339919A4 (en) BICYCLIC DIHYDROIMIDAZOLONE CGRP RECEPTOR ANTAGONISTS
ZA200906849B (en) Mineralcorticoid receptor antagonists for the treatment of endomertriosis
GB2461962B (en) Slow release NMDA receptor antagonist for otic disorders